IE36000L - DERIVATIVES OF 17 Ó-HYDROXY-ANDROST-4-ENE-17ß- CARBOXYLIC¹ACIDS - Google Patents

DERIVATIVES OF 17 Ó-HYDROXY-ANDROST-4-ENE-17ß- CARBOXYLIC¹ACIDS

Info

Publication number
IE36000L
IE36000L IE720082A IE8272A IE36000L IE 36000 L IE36000 L IE 36000L IE 720082 A IE720082 A IE 720082A IE 8272 A IE8272 A IE 8272A IE 36000 L IE36000 L IE 36000L
Authority
IE
Ireland
Prior art keywords
hydroxy
alkyl
novel
products
ene
Prior art date
Application number
IE720082A
Other versions
IE36000B1 (en
Original Assignee
Glaxo Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Lab Ltd filed Critical Glaxo Lab Ltd
Publication of IE36000L publication Critical patent/IE36000L/en
Publication of IE36000B1 publication Critical patent/IE36000B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1384372 Derivatives of 17α-hydroxy-androst- 4 - ene - 17# - carboxylic acid GLAXO LABORATORIES Ltd 20 Jan 1972 [20 Jan 1971] 2787/71 Heading C2U [Also in Division A5] Novel steroids of the formulµ wherein (a) X is H, Cl or F; R 1 is #-OH or, when X is Cl, R 1 may also be #-Cl; R 2 is H, =CH 2 or α- or #-CH 3 ; R 3 is H, C 1-3 alkyl or phenyl; R 4 is C 1-4 alkyl optionally substituted by either at least one halogen or by C 2-5 alkoxycarbonyl, or is (C 2-5 alkanoyloxy)-(C 2-4 alkyl) and the #<SP>1</SP>- double bond is optional; or (b) X is Cl or F; R 1 is = O ; R 3 is CH 3 or C 2 H 5 ; and R 2 , R 4 and the #<SP>1</SP>-double bond are as defined above, but excluding the n- and iso-propyl and n-butyl esters of 17α - formyloxy - 11# - hydroxy - 3 - ketoandrost - 4 - ene - 17# - carboxylic acid and also excluding the C 1-4 alkyl esters of 11#,17α- dihydroxy - 3 - keto - androst - 4 - ene - 17#- carboxylic acid, and the novel anhydrides (including mixed anhydrides) of the free 17#- carboxylic acids, and the novel 2<SP>1</SP>-hydroxyethyl 9α - fluoro - 11# - hydroxy - 16# - methyl - 3- oxo - 17α - propionyloxy - androsta - 1,4 - diene- 17#-carboxylate, are prepared from the corresponding 17α - hydroxy - 17# - carboxy - steroids by standard esterification and acylation procedures. Resulting 11#-ols may be oxidized to 11-ones and 17-acylates may be hydrolysed to 17α-ols and subsequently re-esterified. Acylation of the free 17α-OH-17#-CO 2 H compounds with carboxylic acid anhydrides results in the formation of 17α-esters of the mixed anhydrides which are then subjected to solvolysis to give the free 17#-CO 2 H compounds. Substituents in the alkyl group R 4 may be interconverted by standard procedures or formed from other substituents, e.g. a hydroxyalkyl ester may be prepared, then converted via a sulphonyloxy ester to a halo-alkyl ester or, alternatively, O- acylated. Products wherein R 4 contains an α-halogen atom may be obtained by reacting the 17#- CO 2 H compound with an aldehyde and a hydrohalic acid. #<SP>1,4</SP>-products may be partially reduced to #<SP>4</SP>-products. 17α - Hydroxy - 17# - carboxy - steroid starting materials are prepared by oxidation of pregnanes containing a 17#-COCH 2 OH side chain. This reaction may also be effected on 17α-acyloxy starting materials, giving 17α-acyloxy products. The novel 17α-acyloxy-17#-(esterified carboxy)-steroids of the above formula are antiinflammatory agents and may be incorporated in pharmaceutical compositions (see Heading A5B). [GB1384372A]
IE82/72A 1971-01-20 1972-01-20 Derivatives of 17alpha-hydroxy-androst-4-ene-17beta-carboxylic acids IE36000B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB278771A GB1384372A (en) 1971-01-20 1971-01-20 Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids

Publications (2)

Publication Number Publication Date
IE36000L true IE36000L (en) 1972-07-20
IE36000B1 IE36000B1 (en) 1976-07-21

Family

ID=9745890

Family Applications (1)

Application Number Title Priority Date Filing Date
IE82/72A IE36000B1 (en) 1971-01-20 1972-01-20 Derivatives of 17alpha-hydroxy-androst-4-ene-17beta-carboxylic acids

Country Status (17)

Country Link
JP (1) JPS5611720B1 (en)
AU (1) AU473868B2 (en)
BE (1) BE778285A (en)
CA (1) CA1003820A (en)
CH (1) CH602786A5 (en)
DE (1) DE2202691A1 (en)
DK (1) DK132894C (en)
ES (1) ES399057A1 (en)
FR (1) FR2122539B1 (en)
GB (1) GB1384372A (en)
HK (1) HK34278A (en)
IE (1) IE36000B1 (en)
IL (1) IL38589A (en)
NL (1) NL172511C (en)
NO (1) NO137321C (en)
SE (1) SE383522B (en)
ZA (1) ZA72401B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1438940A (en) * 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
DE2444618C2 (en) * 1974-09-16 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen New Pregnan-21-Acid-Derivatives
DE2365102C2 (en) * 1973-12-21 1982-12-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen New pregnanic acid derivatives
DE2319479C2 (en) * 1973-04-14 1982-10-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Pregnanic acid derivatives, processes for their production and pharmaceutical preparations containing them
GB1514476A (en) * 1974-08-30 1978-06-14 Glaxo Lab Ltd Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates
SE427276B (en) * 1975-04-03 1983-03-21 Hoffmann La Roche PROCEDURE FOR PREPARING D-HOMOSTEROIDS
CH628355A5 (en) * 1976-02-24 1982-02-26 Ciba Geigy Ag METHOD FOR PRODUCING NEW ANDROSTADIEN-17BETA-CARBONIC ACIDS AND THEIR ESTERS AND SALTS.
IT1114534B (en) * 1978-02-08 1986-01-27 Glaxo Group Ltd ANTI-INFLAMMATORY STEROID OF THE ANDROSTANE SERIES COMPOSITIONS THAT CONTAIN IT AND PROCEDURE TO PRODUCE IT
CA1138857A (en) * 1979-01-24 1983-01-04 Leo Alig D-homosteroids
SE449106B (en) * 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd STEROID WITH ANTI-INFLAMMATORY EFFECT AND COMPOSITION CONTAINING THIS
JPS59139315A (en) * 1983-01-31 1984-08-10 Taisho Pharmaceut Co Ltd Cream agent
US4607028A (en) * 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters
US5981517A (en) * 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
CA2417826A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
AR033290A1 (en) 2001-04-30 2003-12-10 Glaxo Group Ltd ANDROSTANO ANTIINFLAMATORY DERIVATIVES
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
EP1653974B1 (en) 2003-06-19 2010-01-06 BODOR, Nicholas S. Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application
WO2004112800A1 (en) 2003-06-19 2004-12-29 Bodor Nicholas S Enhancement of activity and/or duration of action of selected anti-inflammatory steroids
GB0316290D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
JP5281291B2 (en) 2005-01-10 2013-09-04 グラクソ グループ リミテッド New compounds
US7691811B2 (en) 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US7687484B2 (en) 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
DE102010029877A1 (en) 2010-06-09 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Preparing 1,4-pregna-dienoic acid derivative from 20-hydroxysteroid derivative by Swern oxidation, comprises adding 20-hydroxysteroid derivative in mixture of e.g. secondary amine and dimethylsulfoxide, and adding chlorosulfonic acid
DE102010029875A1 (en) 2010-06-09 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Preparing 1,4-pregna-dienoic acid derivatives, comprises oxidizing 20-oxo-steroid derivatives to 20-hydroxysteroid derivatives in the presence of copper(II) salts with hydroxyalkyl, and oxidizing the 20-oxo-steroid derivatives
US8835410B2 (en) 2011-05-10 2014-09-16 Bodor Laboratories, Inc. Treatment of eyelid dermatitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636010A (en) * 1968-12-23 1972-01-18 Ciba Geigy Corp Esters of steroid-17-carboxylic acids

Also Published As

Publication number Publication date
IE36000B1 (en) 1976-07-21
GB1384372A (en) 1975-02-19
IL38589A (en) 1976-06-30
AU3811072A (en) 1973-07-26
ZA72401B (en) 1973-09-26
JPS5611720B1 (en) 1981-03-16
IL38589A0 (en) 1972-03-28
AU473868B2 (en) 1976-07-08
NO137321C (en) 1978-02-08
BE778285A (en) 1972-07-20
DK132894B (en) 1976-02-23
SE383522B (en) 1976-03-15
NO137321B (en) 1977-10-31
CA1003820A (en) 1977-01-18
ES399057A1 (en) 1974-11-01
CH602786A5 (en) 1978-08-15
FR2122539B1 (en) 1975-11-28
NL172511B (en) 1983-04-18
DK132894C (en) 1976-07-26
FR2122539A1 (en) 1972-09-01
HK34278A (en) 1978-07-07
NL7200818A (en) 1972-07-24
DE2202691A1 (en) 1972-08-03
NL172511C (en) 1983-09-16

Similar Documents

Publication Publication Date Title
IE36000B1 (en) Derivatives of 17alpha-hydroxy-androst-4-ene-17beta-carboxylic acids
DE3474025D1 (en) Carboxylic acid esters of steroids
SE8502204L (en) IMPROVEMENT OF HARTS-PENTAERYTRITOL ESTER PREPARATION
GB1490603A (en) Glycerides with anti-inflammatory properties
IE780760L (en) Cephalosporin antibiotics
IE791558L (en) Steroidal lactones
GB1432503A (en) Cycloalkylalkylesters and process for their preparation
GB1374342A (en) Production of carboxylic acid glycidyl esters
IE38659L (en) Pregnane acid derivatives.
GB1473574A (en) Sitosterol esters
DE2967004D1 (en) Mixed anhydride steroid intermediate and process for preparing steroid intermediates
GB1352027A (en) Process for the manufacture of pregnane compounds and process for the manufacture of sulphite esters
JPS5265263A (en) Azetidinone compounds
IE800050L (en) 21-alkylated steroids
IE37657L (en) Prednisolone derivative.
IE40606L (en) Improvements in the preparation of esters of hydroxy¹aromatic carboxylic acids.
GB2017099A (en) beta -Lactam antibiotics preparation
MY104951A (en) Process for the production of phthalazineacbtic acid ester derivatives and a novel intermediate.
GB1130370A (en) Esters of 6-aminopenicillanic acid
GB1479712A (en) 7-amino-3-thiomethyl-cephem-4-carboxylic acid derivatives
IE43594L (en) Pharmaceutical compositions
JPS51131821A (en) Process for preparation of gamma-halo-delta-unsaturated carboxylic acids
DE2966961D1 (en) Prednisone derivatives, process for their production and pharmaceutical preparations containing these compounds
KR900007778A (en) Method for preparing benzoyl malonate derivative
GB1507037A (en) 2,6beta-difluoropregnenes